Fifteen-year trends in metastatic breast cancer survival in Greece

Breast Cancer Research and Treatment

Volumn 119, Issue 3, 2010, Pages 621-631

  Dafni, U ^a   Grimani, I ^b   Xyrafas, A ^a   Eleftheraki, A G ^b   Fountzilas, G ^b,c  

^a UNIVERSITY OF ATHENS   (Greece)

^b Hellenic Cooperative Oncology Group   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

First line chemotherapy; Meta analysis; Metastatic Breast Cancer; Survival temporal trend

Indexed keywords

CARBOPLATIN; DOCETAXEL; EPIRUBICIN; GEMCITABINE; PACLITAXEL; TRASTUZUMAB;

AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FOLLOW UP; GREECE; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VISCERAL METASTASIS;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; GREECE; HISTORY, 16TH CENTURY; HISTORY, 17TH CENTURY; HISTORY, 18TH CENTURY; HUMANS; PROGNOSIS;

EID: 74849132410     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0630-8     Document Type: Article

References (24)

1. R Largillier JM Ferrero J Doyen J Barriere M Namer V Mari A Courdi JM Hannoun-Levi F Ettore I Birtwisle-Peyrottes C Balu-Maestro PY Marcy I Raoust M Lallement E Chamorey 2008 Prognostic factors in 1,038 women with metastatic breast cancer Ann Oncol 19 12 2012 2019 10.1093/annonc/mdn424 1:STN:280:DC%2BD1cjlsFegtQ%3D%3D 18641006
2. J Ferlay P Autier M Boniol M Heanue M Colombet P Boyle 2007 Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 3 581 592 10.1093/annonc/mdl498 1:STN:280:DC%2BD2s7hslSgtw%3D%3D 17287242 (Pubitemid 46359643)
3. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun 2009 Cancer statistics, 2009 CA Cancer J Clin 59 225 249 10.3322/caac.20006 19474385
4. S Dawood K Broglio AM Gonzalez-Angulo AU Buzdar GN Hortobagyi SH Giordano 2008 Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer J Clin Oncol 26 30 4891 4898 10.1200/JCO.2007.14.1168 18725649
5. SH Giordano AU Buzdar TL Smith SW Kau Y Yang GN Hortobagyi 2004 Is breast cancer survival improving? Cancer 100 1 44 52 10.1002/cncr.11859 14692023 (Pubitemid 37553538)
6. A Gennari P Conte R Rosso C Orlandini P Bruzzi 2005 Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies Cancer 104 8 1742 1750 10.1002/cncr.21359 16149088 (Pubitemid 41437440)
7. F Andre K Slimane T Bachelot A Dunant M Namer A Barrelier O Kabbaj JP Spano H Marsiglia R Rouzier S Delaloge M Spielman 2004 Breast cancer with synchronous metastases: Trends in survival during a 14-year period J Clin Oncol 22 3302 3308 10.1200/JCO.2004.08.095 15310773 (Pubitemid 41103686)
8. G Fountzilas D Skarlos C Katsohis N Pavlidis T Giannakakis D Bafaloukos E Fahantidis G Klouvas M Beer P Kosmidis 1995 High-dose epirubicin and r-met-hu G-CSF (filgrastim) in the treatment of patients with advanced breast cancer: a Hellenic Cooperative Oncology Group study Med Pediatr Oncol 24 1 23 28 10.1002/mpo.2950240106 1:STN:280:DyaK2M%2FlvVCruw%3D%3D 7526143 (Pubitemid 24373606)
9. G Fountzilas D Scarlos T Giannakakis A Athanasiades D Bafaloukos A Kalogera-Fountzila C Bamia N Pavlidis P Kosmidis 1994 Intensive chemotherapy with high-dose Epirubicin every 2 weeks and prophylactic administration of Filgrastim in advanced breast cancer Eur J Cancer 30A 7 965 969 10.1016/0959-8049(94)90124-4 1:STN:280:DyaK2M%2FjtlGhsQ%3D%3D 7524579 (Pubitemid 24256244)
10. G Fountzilas A Athanasiades T Giannakakis E Brasoulis D Bafaloukos A Kalogera-Fountzila A Onienaoum H Kalofonos D Pectasides E Andreopoulou C Bamia P Kosmidis N Pavlidis D Skarlos 1997 A randomised study of Epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study Ann Oncol 8 12 1213 1220 10.1023/A:1008270307264 1:STN:280:DyaK1c7lslCksw%3D%3D 9496386 (Pubitemid 28164076)
11. G Fountzilas ΑΜ Dimopoulos C Papadimitriou A Kalogera-Fountzila G Aravantinos D Bafaloukos A Athanassiades C Nicolaides A Keramopoulos N Pavlidis P Kosmidis D Skarlos 1998 First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Oncology Group Ann Oncol 9 9 1031 1034 10.1023/A:1008466928323 1:STN:280:DyaK1M%2FjsFCnsg%3D%3D 9818080 (Pubitemid 28496715)
12. Ε Razis ΑΜ Dimopoulos D Bafaloukos C Papadimitriou A Kalogera-Fountzila H Kalofonos E Briassoulis E Samantas A Keramopoulos N Pavlidis P Kosmidis G Fountzilas 2001 Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer Cancer Invest 19 2 137 144 10.1081/CNV-100000148 1:CAS:528:DC%2BD3MXivVOitbw%3D 11296618 (Pubitemid 32233785)
13. G Fountzilas C Papadimitriou U Dafni D Bafaloukos D Skarlos LA Moulopoulos E Razis HP Kalofonos G Aravantinos E Briassoulis P Papakostas K Abela E Gogas P Kosmidis N Pavlidis ΑΜ Dimopoulos 2001 Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group J Clin Oncol 19 8 2232 2239 1:CAS:528:DC%2BD3MXjsFeru7Y%3D 11304776
14. G Fountzilas D Tsavdaridis A Kalogera-Fountzila CH Christodoulou E Timotheadou HP Kalofonos P Kosmidis A Adamou P Papakostas H Gogas G Stathopoulos E Razis D Bafaloukos D Skarlos 2001 Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer: a Hellenic Cooperative Oncology Group phase II study Ann Oncol 12 11 1545 1551 10.1023/A:1013184301155 1:STN:280:DC%2BD38%2FptlGitg%3D%3D 11822753 (Pubitemid 34065883)
15. G Fountzilas HP Kalofonos U Dafni C Papadimitriou D Bafaloukos P Papakostas A Kalogera-Fountzila H Gogas G Aravantinos LA Moulopoulos T Economopoulos D Pectasides N Maniadakis V Siafaka E Briasoulis C Christodoulou D Tsavdaridis P Makrantonakis E Razis P Kosmidis D Skarlos MA Dimopoulos 2004 Paclitaxel and epirubicin versus paclitaxel and carboplatin, as first line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group Ann Oncol 15 10 1517 1526 10.1093/annonc/mdh395 1:STN:280:DC%2BD2cvlvVKjsQ%3D%3D 15367413 (Pubitemid 39409743)
16. G Fountzilas C Christodoulou D Tsavdaridis A Kalogera-Fountzila G Aravantinos E Razis HP Kalofonos P Papakostas M Karina H Gogas D Skarlos 2004 Paclitaxel and gemcitabine as a first-line chemotherapy combined with trastuzumab in patients with advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) Cancer Invest 22 5 655 662 10.1081/CNV-200032980 1:CAS:528:DC%2BD2cXosFShsro%3D 15581045 (Pubitemid 40064724)
17. G Fountzilas U Dafni MA Dimopoulos A Koutras D Skarlos P Papakostas H Gogas D Bafaloukos A Kalogera-Fountzila E Samantas E Briasoulis D Pectasides N Maniadakis F Matsiakou G Aravantinos C Papadimitriou M Karina C Christodoulou P Kosmidis HP Kalofonos 2009 A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer. A Hellenic Cooperative Oncology Group study Breast Cancer Res Treat 115 1 87 99 10.1007/s10549-008-0047-9 1:CAS:528: DC%2BD1MXkvVyqsr0%3D 18483853
18. CT Smith PR Williamson AG Marson 2005 An overview of methods and empirical comparison of aggregate data and individual patient data results for investigating heterogeneity in meta-analysis of time-to-event outcomes J Eval Clin Pract 11 5 468 478 10.1111/j.1365-2753.2005.00559.x 16164588 (Pubitemid 41376598)
19. CT Smith PR Williamson AG Marson 2005 Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes Stat Med 15 24 9 1307 1319 10.1002/sim.2050 (Pubitemid 40585170)
20. Information about RevMan available at the relevant web site of Cochrane Collaboration: http://www.cc-ims.net/RevMan
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analysis. BMJ 327(7414):557-560. Review
22. JJ Shuster 1991 Median follow up in clinical trials J Clin Oncol 9 1 191 192 1:STN:280:DyaK3M%2Fos12muw%3D%3D 1985169
23. SK Chia CH Speers Y D'yachkova A Kang S Malfair-Taylor J Barnett A Coldman KA Gelmon SE O'Reilly IA Olivotto 2007 The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer Cancer 110 5 973 979 10.1002/cncr.22867 17647245 (Pubitemid 47312861)
24. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2 N Engl J Med 344 783 792 10.1056/NEJM200103153441101 1:CAS:528: DC%2BD3MXisVGktrc%3D 11248153 (Pubitemid 32222155)